Whilst the results read ok its not exactly a large trial with only 12 patients and they only take BIT225 for 28days whilst they are mainly on IFN/RBV over the 48 weeks. Why isnt BIT225 the main drug.
Whilst they all benefited after 24weeks only information from a subset benefited up to 48weeks , does it mean only a subset of patients and not all benefited out to 48weeks.
"12 patients received IFN/RBV for 7 days before commencing treatment with BIT225. They then received 300 mg BIT225 twice daily plus IFN/RBV for 28 days. After that time, patients continued to take IFN/RBV for 48 weeks"
"All HCV genotype 3 patients completing treatment are virus-free at 24 weeks ? Preliminary data from subset of patients shows benefit extends out to 48 weeks"
If there is anything in all this expect a large cap raising with broker support as under $1m left in kitty come the quarter close.
BIT Price at posting:
17.0¢ Sentiment: None Disclosure: Not Held
